This phenomenon may be ascribed to the myeloablative environment induced by ASCT, which stimulates specific CD8+ T cell expansion after CAR-T reinfusion and triggers an immune response, thereby enhancing the anti-tumor effect [36]. Here, CD8A is linked to neoplasm.